Aigen Investment Management LP Has $604,000 Holdings in Waters Corporation $WAT

Aigen Investment Management LP cut its stake in Waters Corporation (NYSE:WAT) by 52.2% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,590 shares of the medical instruments supplier’s stock after selling 1,737 shares during the period. Aigen Investment Management LP’s holdings in Waters were worth $604,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its holdings in Waters by 3.3% during the third quarter. Vanguard Group Inc. now owns 7,656,891 shares of the medical instruments supplier’s stock worth $2,295,612,000 after purchasing an additional 246,128 shares during the last quarter. Fundsmith LLP boosted its holdings in Waters by 9.6% during the third quarter. Fundsmith LLP now owns 3,955,498 shares of the medical instruments supplier’s stock worth $1,185,898,000 after purchasing an additional 347,091 shares during the last quarter. Geode Capital Management LLC boosted its holdings in Waters by 0.5% during the fourth quarter. Geode Capital Management LLC now owns 1,593,388 shares of the medical instruments supplier’s stock worth $602,921,000 after purchasing an additional 8,590 shares during the last quarter. Invesco Ltd. boosted its holdings in Waters by 32.3% during the third quarter. Invesco Ltd. now owns 1,472,419 shares of the medical instruments supplier’s stock worth $441,446,000 after purchasing an additional 359,596 shares during the last quarter. Finally, Fundsmith Investment Services LTD. boosted its holdings in Waters by 11.1% during the third quarter. Fundsmith Investment Services LTD. now owns 1,356,289 shares of the medical instruments supplier’s stock worth $406,629,000 after purchasing an additional 135,504 shares during the last quarter. 94.01% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts recently commented on WAT shares. Wolfe Research started coverage on shares of Waters in a report on Tuesday, June 2nd. They set an “outperform” rating and a $425.00 target price for the company. UBS Group increased their target price on shares of Waters from $330.00 to $375.00 and gave the stock a “neutral” rating in a report on Wednesday, May 6th. Wells Fargo & Company increased their price target on shares of Waters from $355.00 to $370.00 and gave the company an “equal weight” rating in a research note on Thursday, May 14th. Weiss Ratings reiterated a “hold (c)” rating on shares of Waters in a research note on Monday, April 20th. Finally, Robert W. Baird set a $387.00 price target on shares of Waters in a research note on Wednesday, May 6th. Three investment analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $394.56.

Waters Stock Performance

Shares of WAT stock opened at $355.10 on Monday. The stock has a market cap of $34.87 billion, a P/E ratio of 45.12, a P/E/G ratio of 2.15 and a beta of 1.21. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.79 and a quick ratio of 1.13. The company has a fifty day moving average price of $337.69 and a two-hundred day moving average price of $349.91. Waters Corporation has a one year low of $275.05 and a one year high of $414.15.

Waters (NYSE:WAT) last announced its quarterly earnings results on Tuesday, May 5th. The medical instruments supplier reported $2.70 EPS for the quarter, beating analysts’ consensus estimates of $2.31 by $0.39. The firm had revenue of $1.27 billion during the quarter, compared to analysts’ expectations of $1.20 billion. Waters had a net margin of 11.91% and a return on equity of 15.60%. The company’s revenue for the quarter was up 91.4% compared to the same quarter last year. During the same quarter last year, the company posted $2.25 earnings per share. Waters has set its Q2 2026 guidance at 2.950-3.050 EPS and its FY 2026 guidance at 14.400-14.600 EPS. As a group, equities analysts predict that Waters Corporation will post 14.51 EPS for the current year.

Waters Profile

Waters Corporation is a global provider of analytical instruments, software and services for laboratory and research applications. The company designs, manufactures and sells technologies centered on liquid chromatography, mass spectrometry, separation science, and related sample preparation and detection systems. Its product portfolio includes chromatographs, mass spectrometers, columns and consumables, laboratory informatics and workflow software, as well as technical support and training services that help customers run and interpret complex analyses.

Waters serves a wide range of end markets that include pharmaceutical and biotechnology companies, contract research and testing laboratories, academic and government research institutions, clinical diagnostics, food and environmental testing, and industrial and chemical manufacturers.